Vertex Pharmaceuticals (VRTX) risk factors, 2025 10-K

Risks Related to Our Business

1. 01If we are unable to successfully develop and commercialize additional products, our business could be materially harmed
2. 02If we are unable to sustain and grow revenues from sales of our CF medicines, our business would be materially harmed and the market price of our common stock would likely decline
3. 03If we are unable to successfully develop, obtain approval and commercialize treatments for acute and neuropathic pain, our business could be materially harmed
4. 04If we are not successful in commercializing CASGEVY, our revenue growth could be limited and our business could be materially harmed
5. 05If our competitors bring products with superior product profiles to market, our products may not be competitive, and our revenues could decline
6. 06If we discover safety issues with any of our products or if we fail to comply with continuing U.S. and applicable foreign regulations, commercialization efforts for the product could be negatively affected, the approved product could lose its approval, and our business could be materially harmed
7. 07If physicians and patients do not accept our products, or if patients do not remain on treatment or comply with their prescribed dosing regimen, our product revenues would decline in future periods
8. 08Cell and genetic therapies face increased scrutiny from the public and medical communities and commercial success will depend, in part, upon the acceptance of those communities

Risks Related to Pricing of Our Products

1. 09Government and other third-party payors seek to contain costs of health care through legislative and other means. If they fail to provide coverage and adequate reimbursement rates for our products, our revenues will be harmed
2. 10revenues. Our business would be materially adversely affected if we are not able to obtain or maintain coverage and reimbursement of our products from third-party payors on a broad, timely, or satisfactory basis, or if such coverage is subject to overly broad or restrictive utilization management controls
3. 11We may experience pricing pressure on our products, which could reduce our revenues and future profitability
4. 12We have experienced challenges commercializing products outside of the U.S., and our future revenues will be dependent on our ability to obtain adequate reimbursement for our products in ex-U.S. markets
5. 13Insurance coverage and reimbursement of cell and genetic therapies is uncertain

Risks Related to Development and Clinical Testing of Our Products and Product Candidates

1. 14Our product candidates remain subject to clinical testing and regulatory approval, and our future success is dependent on our ability to successfully develop additional product candidates for both CF and non-CF indications
2. 15provide the level of evidence or safety and efficacy required by the FDA or other regulatory authorities for approval of a product candidate. Finally, clinical trials are expensive and require significant operational resources to implement and maintain
3. 16If we are unable to obtain or are delayed in obtaining regulatory approval, we may incur additional costs, experience delays, or be unable to commercialize our product candidates
4. 17If clinical trials are prolonged or delayed, our development timelines for the affected development program could be extended, our costs to develop the product candidate could increase and the competitive position of the product candidate could be adversely affected
5. 18Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or prevent regulatory approval
6. 19Enrollment for clinical trials for our cell and gene therapies may face additional and unique challenges and adverse developments associated with these clinical trials could result in action by regulatory bodies, including revised requirements for approval

Risks Related to Government Regulation

1. 20interactions with a broader set of healthcare practitioners. Failure to comply with the reporting requirements could result in significant civil monetary penalties
2. 21If our processes and systems are not compliant with regulatory requirements, we could be subject to restrictions on marketing our products or could be delayed in submitting regulatory filings seeking approvals for our product candidates
3. 22The regulatory approval process for our cell or genetic therapies involves additional consultations with regulatory agencies, costs, and potentially longer timelines as compared to those for small molecules
4. 23We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could adversely affect our business, result in fines and/or criminal penalties, and damage our reputation
5. 24If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected

Risks Related to Supply, Manufacturing and Reliance on Third Parties

1. 25We may face manufacturing, supply, and distribution difficulties, among other challenges, delays, or interruptions, including at our third-party providers
2. 26be able to agree on contractual terms with third parties as needed for manufacturing of our products. Although we attempt to manage the business relationships with our partners, we could be subject to supply disruptions outside of our control
3. 27We rely on third parties to conduct pre-clinical work, clinical trials and other activities, and those third parties may not perform satisfactorily, including failing to meet established deadlines for the completion of such studies and/or trials or failing to satisfy regulatory requirements

Risks Related to Business Development Activities

1. 28We face risks in connection with existing and future collaborations with respect to the development, manufacture and commercialization of our products and product candidates
2. 29Our ability to execute on our long-term strategy depends in part on our ability to engage in transactions and collaborations with other entities that add to our pipeline or provide us with new commercial opportunities
3. 30We may not realize the anticipated benefits of existing or future acquisitions of businesses or technologies, and the integration following any such acquisition may disrupt our business and management

Risks Related to Intellectual Property

1. 31If our patents do not protect our products or our products infringe third-party patents, we could be subject to litigation which could result in injunctions preventing us from selling our products, substantial damages, or circumvention of our patents by third parties
2. 32Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes that are inherently costly and unpredictable
3. 33We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property

Risks Related To Our Operations

1. 34If we fail to scale our operations to accommodate growth, our business may suffer
2. 35A variety of risks associated with operating in foreign countries could materially adversely affect our business
3. 36Our business has a substantial risk of product liability claims and other litigation liability
4. 37A breakdown or breach of our information technology systems could subject us to liability or interrupt the operation of our business
5. 38We rely on third parties to carry out our operations. Failure to maintain our third-party relationships or challenges at or with these third parties could materially harm our business
6. 39If we fail to attract and retain skilled employees, our business could be materially harmed
7. 40If our facilities were to experience a catastrophic loss, our operations would be seriously harmed
8. 41The use of social media platforms and artificial intelligence tools presents risks and challenges

Risks Related to Financial Results and Holding Our Common Stock

1. 42Our stock price may fluctuate
2. 43Our effective tax rate fluctuates, and changes in tax laws, regulations and treaties, unfavorable resolution to the tax positions we have taken or exposure to additional income tax liabilities could have a material impact on our future taxable income
3. 44Our quarterly operating results are subject to significant fluctuation
4. 45We expect that results from our clinical development activities and the clinical development activities of our competitors will continue to be released periodically, and may result in significant volatility in the price of our common stock
5. 46Future indebtedness could materially and adversely affect our financial condition, and the terms of our credit agreements impose restrictions on our business, reducing our operational flexibility and creating default risks
6. 47Issuances of additional shares of our common stock could cause the price of our common stock to decline
7. 48There can be no assurance that we will repurchase shares of common stock or that we will repurchase shares at favorable prices
8. 49We have adopted provisions in our articles of organization and by-laws and are subject to Massachusetts corporate laws that may frustrate any attempt to remove or replace members of our board or to effectuate certain types of business combinations involving us
9. 50SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS